Sandoz welcomes the Ontario Government introduction of biosimilars switch policy to expand the use of biosimilars available on the market and generate significant cost savings to the province healthcare system. Biosimilars are not new. There is extensive use of biosimilars in Canada including 50 biosimilars already approved for use in the Canadian market to date. Health Canada is clear that physician-supervised switching is a safe and efficacious practice, and the safety and efficacy of switching patients to biosimilars is also well established internationally and supported by numerous studies. "Biosimilar switch policies are an important step towards increasing patient access to quality and potentially life-enhancing biosimilar medicines they need while realizing significant health system cost savings. We support the promotion of wider adoption of biosimilars to reinvest savings into healthcare resources and enable more patients to experience the benefits of biologic treatment," said Michel Robidoux, President and General Manager at Sandoz Canada and Chair of Biosimilars Canada.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Novartis call volume above normal and directionally bullish
- Harrow Health signs binding agreement to acquire rights to ophthalmic products
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Novartis reports Phase 3 APPLY-PNH trial met both primary endpoints
- Novartis’ (NYSE:NVS) Advanced Prostate Cancer Therapy Bags EU Approval